In this edition: The newest players in longevity, and why you should probably buy travel health insurance.

The women of the longevity industry. In the high-profile pursuit of lifespans extending to 100 and beyond, men have been the faces of the movement. That is starting to change with the rise of an increasingly prominent group of female scientists, entrepreneurs and influencers. In a field dominated by “longevity bros,” they could be called the “longevity ladies.”

Cancer and the Manhattan Project. People who grew up in the 1940s, ’50s or ’60s around Coldwater Creek in St. Louis County–near where uranium was processed during WWII–faced a heightened risk of cancer, new research suggests.

Juul Labs’ e-cigarettes get FDA nod. Federal regulators will allow the vaping company’s e-cigarettes–and tobacco and menthol-flavored refills, to remain on the U.S. market, according to people familiar with the matter. The decision breathes new life into Juul after a federal ban in 2022 pushed it to the brink of bankruptcy.

Why you should buy travel health insurance. Few things can wreck a vacation like an unexpected trip to the doctor or emergency room, especially in a foreign country. Credit-card and U.S. health-insurance providers may offer some coverage abroad. But it’s critical to read the fine print ahead of a trip to see exactly what is—and isn’t—covered.

A lower-energy energy drink? Liquid Death, the six-year-old brand best known for selling water in large beer cans emblazoned with dripping skulls, is moving into the energy drinks aisle. The hook? Its offering, Sparkling Energy, will be less loaded with caffeine than most new entrants.

Direct-to-consumer drugs. Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price—a move that follows the Trump administration’s pressure on the industry to cut drug prices. Eliquis has a list price of $606 for a 30-day supply; the discounted cash price will be $346 a month.

Wall Street shrugs off threats of pharma tariffs. Since President Trump said that imported drugs would face a 200% levy, investors have been cautiously celebrating. They focused on a grace period of a year to a year and a half that Trump floated. With more time to prepare, pharma companies may barely feel the sting.

Private equity makes bet on biopharma. Private-equity firms Bain Capital and Kohlberg are leading a new multibillion-dollar investment in PCI Pharma Services, a company that specializes in helping biopharma companies bring new drugs to market. The deal values PCI at $10 billion, including debt.

This newsletter was compiled by the WSJ’s Health & Science team. Follow us on X @WSJHealth and @WSJScience. Email us by replying to this newsletter.